IKT is the ticker symbol for Inhibikase Therapeutics, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks IKT with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is IKT a good stock to buy?

IKT is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/IKT.

Where does 13F Pro source IKT data?

All Inhibikase Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Inhibikase Therapeutics, Inc. files with the SEC under CIK 1750149. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Inhibikase Therapeutics, Inc.(IKT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Inhibikase Therapeutics, Inc. (IKT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. IKT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $3.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Inhibikase Therapeutics, Inc. reports net income of $-19.6M, free cash flow of $-12.4M. Top institutional holders of IKT by reported 13-F value include Sands Capital Ventures, Soleus Capital Management, L.P., Trails Edge Capital Partners, based on the most recent SEC filings. IKT trades on the Nasdaq exchange and files with the SEC under CIK 1750149. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IKT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inhibikase Therapeutics, Inc. directly from SEC EDGAR.

Revenue

$0.00

Net Income

$-19.6M

Free Cash Flow

$-12.4M

IKT key financials by period

Inhibikase Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2023	10-K	$260.5K	$-19.0M	—
FY 2022	10-K	$123.4K	$-18.1M	—
FY 2021	10-K	$3.1M	$-14.8M	—
FY 2020	10-K	$698.5K	$-2.8M	—

Institutions holding IKT

Institutional investors reporting a position in Inhibikase Therapeutics, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
Sands Capital Ventures	13,018,965	$26.4M	2026-06-30
Soleus Capital Management, L.P.	10,875,000	$22.1M	2026-06-30
Trails Edge Capital Partners	9,051,318	$18.4M	2026-06-30
Fairmount Funds Management	8,625,000	$17.5M	2026-06-30
BlackRock	7,768,057	$15.8M	2026-06-30
ADAR1 Capital Management	7,387,205	$15.0M	2026-06-30
Blackstone	5,938,276	$12.1M	2026-06-30
Siren, L.L.C.	5,850,000	$11.9M	2026-06-30
Commodore Capital	5,397,488	$11.0M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	4,935,354	$10.0M	2026-06-30

SEC EDGAR: CIK 1750149 →

Inhibikase Therapeutics, Inc.

IKT

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $3.1M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.